Table 2

Associations between sST2 and the primary (any cardiovascular event) and secondary endpoints (death or heart failure), with adjustment for clinical characteristics

HR per twofold higher value95% CIP value
Any cardiovascular event (n=225)
sST2 (univariable)1.301.07 to 1.570.007
Adjusted for age and sex1.471.19 to 1.81<0.001
Adjusted for age, sex and creatinine1.441.17 to 1.78<0.001
Adjusted for age, sex and NT-proBNP1.281.04 to 1.570.022
Adjusted for age, sex, NT-proBNP and creatinine1.281.03 to 1.580.025
Adjusted for age, sex, rhythm and systemic ventricular function1.461.19 to 1.79<0.001
Adjusted for age, sex, congenital diagnosis*, NYHA class and cardiac medication1.291.05 to 1.580.016
Full model†1.281.05 to 1.590.017
Full model† and NT-proBNP1.190.96 to 1.480.106
Death or heart failure (n=69)
sST2 (univariable)1.481.04 to 2.100.029
Adjusted for age and sex2.231.50 to 3.30<0.001
Adjusted for age, sex and creatinine2.161.45 to 3.22<0.001
Adjusted for sex, age and NT-proBNP1.480.99 to 2.220.059
Adjusted for sex, age, NT-proBNP and creatinine1.571.03 to 2.390.036
Adjusted for age, sex, rhythm and systemic ventricular function2.131.46 to 3.12<0.001
Adjusted for age, sex, congenital diagnosis*, NYHA class and cardiac medication1.601.10 to 2.340.015
  • *Congenital diagnosis of arterial switch operation, aortic stenosis or aortic coarctation (0) versus tetralogy of Fallot, Rastelli, systemic right ventricle, univentricular heart or pulmonary arterial hypertension (1). 

  • †Adjusted for age, sex, creatinine, sinus rhythm, systemic ventricular function, congenital diagnosis, NYHA class 2–3 and cardiac medication. Analysis including all covariates (full model) was not performed for the secondary endpoint due to insufficient statistical power.

  • NT-proBNP, N terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; sST2, soluble suppression of tumourigenicity-2.